News Archive

2014
12.3.2015

Norwich announces major investment

Norwich Pharmaceuticals (“Norwich”) is excited to announce a recent decision by its parent organization (Alvogen) to provide major capital investment in Plant and equipment. Starting immediately, there will be a projected investment of $26 million over the next two years, focused on increasing manufacturing capacity.


11.3.2015

Supreme Court agrees with Natco/Alvogen and denies petition for certiorari on generic Tamiflu patent

Alvogen and Natco Pharma Limited (“Natco”), who have partnered on the first Abbreviated New Drug Application containing a paragraph IV certification filed with the U.S. Food and Drug Administration for the generic version of Tamiflu® oral capsules (oseltamivir phosphate), are pleased with the Supreme Court’s decision to deny certiorari. The denial was issued on March 9, 2015, in the case of Gilead Sciences, Inc. et al. v. Natco Pharma Limited et al, No. 14-647.


15.7.2014

Alvogen wins DIANA “Oscar” for the second consecutive year

For the second year in a row, Alvogen U.S. was this year’s recipient of HDMA’s Distribution Industry Award for Notable Achievement in Healthcare (DIANA) in the category of Best Overall Generic Pharmaceutical Manufacturer with sales to Healthcare Distributors. This once more places Alvogen as the top generic company in the US in their category.


23.4.2014

Federal Circuit agrees with Natco on Generic Tamiflu Patent

Alvogen and Natco Pharma Limited  (“Natco”), who  have partnered on  the first Abbreviated New Drug Application containing a paragraph IV certification filed with the U.S. Food and Drug Administration for the generic version of   Tamiflu® oral capsules (oseltamivir phosphate), are pleased with the Federal Circuit’s decision. 


2013 and older
14.6.2010

Alvogen opens new R&D center of excellence

Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals.


4.5.2010

Alvogen teams up with Orchid in India

Alvogen today announced that it has entered into an agreement with Orchid Chemicals & Pharmaceuticals. Alvogen will market eight high potential oral products from Orchid in the US market, with ...


27.4.2010

Alvogen expands its operations in India

Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that it has expanded its operations in India, by establishing own clinical research organization (“CRO”) and...


15.4.2010

Alvogen appoints team of experienced business development leaders

Alvogen Inc, the US-based generic pharmaceutical company, today announces that it has added to its Global Business Development and R&D teams. These appointments will further strengthen Alvogen’s capability to ...


30.3.2010

Alvogen appoints three new top executives

Alvogen Inc. the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board. The new executives have an outstanding track record in the generic industry ...


14.1.2010

Alvogen Announces Expansion in Romania.

Alvogen today announced that it has expanded operations in Eastern Europe and has opened an office in Bucharest, Romania.


15.12.2009

Alvogen Launches Asia Operations

Multinational pharmaceuticals company establishes foothold in critical Chinese market


22.10.2009

Alvogen acquires research and development capabilities and enters into multi-product development deal with Par Pharmaceutical

As part of the agreement, Alvogen and Par have entered into a multi-year agreement for the development of several high-value, first-to-file generic product opportunities.


29.7.2009

Robert Wessman joins Alvogen

Robert Wessman and Alvogen Group combine to build a leading international generics company